Form 4: Immunic Inc. CFO Glenn Whaley Acquires 265,000 Stock Options

Immunic Inc.'s Chief Financial Officer, Glenn Whaley, has acquired 265,000 stock options, according to a recent SEC filing.

Summary

• Glenn Whaley, the Chief Financial Officer of Immunic Inc., has been granted 265,000 stock options.
• The options were granted on December 4, 2024, with an exercise price of $1.25 per share.
• The options vest over a period of 48 months, with 25% vesting on the first anniversary of the grant date and the remainder vesting monthly over the following 36 months.
• The options expire on December 4, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 48 months is typical for such grants, encouraging long-term commitment.
• The exercise price of $1.25 is specific to the company's stock price at the time of the grant.

Stakeholder Impact

• The stock option grant aligns the CFO's interests with those of shareholders, potentially leading to increased value.

Key Dates

Keywords

stock options, insider trading, SEC Form 4, executive compensation, Immunic Inc., IMUX, Glenn Whaley, CFO